Torti Frank, President and Vant Chair at Roivant Sciences Ltd. ($ROIV), sold shares on the open market three times in the last 365 days for a total of $82 million. His most recent sale occurred on February 23, 2026. These sales rank 194th among nearly 12,000 individual insiders in our database, outpacing the average of $8.6 million per seller across about six transactions. Torti Frank made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 7, 2026 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Stock Option (right to buy) | 88325 | $0.00 | 88,325.0000 | 203,532,180 | 9999.99% | 0.04% |
| April 7, 2026 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Common Stock | 174189 | $0.00 | 1,009,228.0000 | 203,532,180 | 20.86% | 0.09% |
| March 31, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | F | Common Shares | 160035 | $27.70 | 13,576,512.0000 | 696,859,682 | 1.17% | 0.02% |
| Feb. 19, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Common Shares | 1400000 | $3.85 | 15,136,547.0000 | 696,859,682 | 10.19% | 0.20% |
| Feb. 19, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | S | Common Shares | 1400000 | $27.42 | 13,736,547.0000 | 696,859,682 | 9.25% | 0.20% |
| Feb. 20, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Common Shares | 1012610 | $3.85 | 14,749,157.0000 | 696,859,682 | 7.37% | 0.15% |
| Feb. 20, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | S | Common Shares | 1012610 | $27.15 | 13,736,547.0000 | 696,859,682 | 6.87% | 0.15% |
| Feb. 23, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Common Shares | 587390 | $3.85 | 14,323,937.0000 | 696,859,682 | 4.28% | 0.08% |
| Feb. 23, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | S | Common Shares | 587390 | $27.51 | 13,736,547.0000 | 696,859,682 | 4.10% | 0.08% |
| Feb. 19, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Stock Option (Right to Buy) | 1400000 | $0.00 | 4,626,184.0000 | 696,859,682 | 23.23% | 0.20% |
| Feb. 20, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Stock Option (Right to Buy) | 1012610 | $0.00 | 3,613,574.0000 | 696,859,682 | 21.89% | 0.15% |
| Feb. 23, 2026 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | M | Stock Option (Right to Buy) | 587390 | $0.00 | 3,026,184.0000 | 696,859,682 | 16.26% | 0.08% |
| Dec. 24, 2025 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | G | Common Shares | 110489 | $0.00 | 13,736,547.0000 | 680,947,866 | 0.80% | 0.02% |
| Dec. 24, 2025 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | J | Common Shares | 64891 | $22.47 | 13,847,036.0000 | 680,947,866 | 0.47% | 0.01% |
| Dec. 23, 2025 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | A | Common Shares | 175380 | $22.45 | 13,911,927.0000 | 680,947,866 | 1.28% | 0.03% |
| July 30, 2025 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | A | Common Shares | 1836547 | $0.00 | 1,836,547.0000 | 725,395,624 | 9999.99% | 0.25% |
| July 30, 2025 | Roivant Sciences Ltd. | $ROIV | Torti Frank | President and Vant Chair | A | Common Shares | 11900000 | $0.00 | 13,736,547.0000 | 725,395,624 | 647.96% | 1.64% |
| April 1, 2025 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Stock Option (right to buy) | 93599 | $0.00 | 93,599.0000 | 0 | 9999.99% | 0.00% |
| April 1, 2025 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Common Stock | 199365 | $0.00 | 835,039.0000 | 0 | 31.36% | 0.00% |
| May 23, 2024 | Arbutus Biopharma Corp | $ABUS | Torti Frank | Director | A | Stock Option (Right to Buy) | 67000 | $0.00 | 67,000.0000 | 0 | 9999.99% | 0.00% |
| April 2, 2024 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Stock Option (right to buy) | 50167 | $0.00 | 50,167.0000 | 0 | 9999.99% | 0.00% |
| April 2, 2024 | Immunovant, Inc. | $IMVT | Torti Frank | Director | A | Common Stock | 120400 | $0.00 | 635,674.0000 | 0 | 23.37% | 0.00% |
| May 24, 2023 | Arbutus Biopharma Corp | $ABUS | Torti Frank | Director | A | Stock Option (Right to Buy) | 55000 | $0.00 | 55,000.0000 | 0 | 9999.99% | 0.00% |